Back to News
Market Impact: 0.25
WuXi XDC Grants Ona Therapeutics Global Rights To WuXiTecan-2 Payload-Linker Platform
Source: Nasdaq
Healthcare & BiotechPatents & Intellectual PropertyTechnology & Innovation
WuXi XDC Cayman entered an out-licensing agreement granting Ona Therapeutics exclusive worldwide rights to its proprietary WuXiTecan-2 antibody-drug conjugate payload-linker technology. The agreement supports commercialization of WuXi XDC's bioconjugation intellectual property, although the provided article excerpt does not disclose financial terms, development milestones, or royalty details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
More News
- Asian stocks rise as oil retreat eases inflation fears, BOJ in focus
- Microsoft exec called AI scraping the “largest theft of labor in human history”
- Jensen Huang says Nvidia will sell twice as many chips next year
- Generac shares surge on big Amazon deal. Wall Street thinks the generator stock has more to go
- After being sidelined, Boeing's Starliner to get starring role in NASA's spaceflight plans
- This AI-picked stock jumps 18% on Amazon’s $8 billion power deal
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: New Reporting Features and More Sources for Document Search
- How to Evaluate AI Report Writers for Financial Analysis